Europe’s life‑science engine boasts world‑class labs from the Oxford‑Cambridge corridor to biotech hubs in Switzerland, France and the Nordics. Yet funding streams and breakthrough research still sit in separate corners. In 2025, European biotech firms attracted €3.6bn, while drug‑discovery companies secured €4.3bn. This capital surge underscores investors’ confidence in Europe’s pipeline of novel therapeutics.

Project lead Lara Formichella launched the bio:cap conference to bridge that gap. She convenes CEOs, founders, investors and academic researchers who rarely cross paths, aiming to align discovery pipelines with capital and industry expertise. By fostering early‑stage dialogue, the event hopes to turn isolated breakthroughs into market‑ready therapies faster. The agenda includes panels on AI‑driven drug design and cross‑border regulatory harmonisation.

Investors watching the €3.6bn biotech inflow see the conference as a chance to source deals before they appear in traditional pipelines. For startups, bio:cap offers exposure to funding that has already amassed €3.4bn this year, reducing the time between lab success and financing. Analysts note that tighter networks could improve exit multiples for European biotech exits.